The post SIREN crashes 66%: Is $0.46 support about to be tested? appeared on BitcoinEthereumNews.com. Siren [SIREN] has dropped sharply to $0.9994 after losingThe post SIREN crashes 66%: Is $0.46 support about to be tested? appeared on BitcoinEthereumNews.com. Siren [SIREN] has dropped sharply to $0.9994 after losing

SIREN crashes 66%: Is $0.46 support about to be tested?

For feedback or concerns regarding this content, please contact us at [email protected]

Siren [SIREN] has dropped sharply to $0.9994 after losing 66.43% in 24 hours, at press time, and the move reflected clear deterioration in participation across the market. 

At the same time, volume has fallen by 55.18% to $93.34 million, and this decline suggests traders have not stepped in to absorb the sell-off. Instead, reduced activity signals hesitation and lack of confidence during the drop. 

As a result, the structure does not show signs of demand returning, and the absence of strong buying interest continues to expose SIREN to further downside pressure.

SIREN breakdown accelerates as RSI confirms weakness

Price has rejected sharply after a vertical expansion phase, and the structure now reflects a clear breakdown from recent highs. 

SIREN has already lost the $0.9015 support level, which previously acted as a key reaction zone during the rally. This shift now places $0.4645 as the next major support, while a failure there could expose $0.0813 as the lower historical base. 

However, price continues to trade below the breakdown zone without signs of stabilization. On the other hand, the RSI has dropped to around 53.12 as of writing, reflecting a rapid loss of buyer strength after the peak. 

Although RSI has not reached oversold levels, it continues trending lower alongside price, which reinforces the ongoing weakness and supports the broader shift toward sustained downside pressure.

Source: TradingView

SIREN short dominance persists across Binance positioning

Binance top trader positioning continues to favor shorts, and this alignment strengthens the bearish outlook.  At the time of writing, short positions accounted for 55.61% of total positions, while longs stood at 44.39%, leaving the Long/Short ratio at 0.80. 

This imbalance shows that experienced traders continue to position for further downside even after the steep decline. In addition, the persistence of this short bias suggests that market participants do not expect immediate recovery. 

As price struggles to reclaim lost levels, trader positioning remains aligned with the ongoing bearish structure, reinforcing continued downside pressure across the market.

Source: CoinGlass

Negative funding highlights rising bearish conviction

Funding Rates have turned negative, and the OI-Weighted Funding Rate was at -0.0449% as of writing, reflecting strong short-side conviction. This shift shows that short traders continue to pay to maintain their positions, which confirms sustained bearish sentiment in the derivatives market. 

Earlier periods showed mixed funding, but the current persistent negative trend signals growing confidence in downside continuation. 

Besides, this imbalance does not yet indicate exhaustion, as no sharp reversal in funding appears. As a result, derivatives positioning continues to support the broader bearish structure seen across price and market participation.

Source: CoinGlass

SIREN remains firmly under bearish control as weak demand, declining RSI, and dominant short positioning continue to align with downside pressure. 

Price has already lost key support and shows no signs of stabilization, while funding rates and trader positioning reinforce continued selling interest. Given this structure, the current trend favors further downside toward lower support levels rather than recovery.


Final Summary

  • Persistent weakness in demand and structure suggests sellers remain firmly controlling SIREN’s direction ahead. 
  • Continued short dominance across derivatives and spot behavior indicates downside pressure could extend before any meaningful recovery attempt.

Source: https://ambcrypto.com/siren-crashes-66-is-0-46-support-about-to-be-tested/

Market Opportunity
SIREN Logo
SIREN Price(SIREN)
$2.219
$2.219$2.219
+117.76%
USD
SIREN (SIREN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
Why YouCam AI API is the Secret Weapon for E-Commerce Startups

Why YouCam AI API is the Secret Weapon for E-Commerce Startups

 The New Standard of Personalized Shopping In an era where digital engagement dictates market share, the transition from “browsing” to “buying” depends on confidence
Share
Techbullion2026/03/25 14:34
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26